Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products.
The company offers ImprimisRx, an ophthalmology-focused compounded medications.
It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis.
In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop.
Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products.
The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023.
Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.18 Decreased by -28.57% | -0.20 Increased by +10.00% |
| May 13, 24 | -0.38 Decreased by -72.73% | -0.20 Decreased by -90.00% |
| Mar 19, 24 | -0.25 Decreased by -725.00% | -0.04 Decreased by -525.00% |
| Nov 13, 23 | -0.13 Increased by +45.83% | 0.04 Decreased by -425.00% |
| Aug 9, 23 | -0.14 Increased by +39.13% | -0.04 Decreased by -250.00% |
| May 11, 23 | -0.22 Decreased by -833.33% | -0.05 Decreased by -340.00% |
| Mar 23, 23 | 0.04 Increased by +114.81% | -0.12 Increased by +133.33% |
| Nov 14, 22 | -0.24 Increased by +22.58% | -0.01 Decreased by -1.70 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 49.26 M Increased by +43.75% | -4.22 M Increased by +3.89% | Decreased by -8.57% Increased by +33.15% |
| Jun 30, 24 | 48.94 M Increased by +46.22% | -6.47 M Decreased by -53.06% | Decreased by -13.23% Decreased by -4.68% |
| Mar 31, 24 | 34.59 M Increased by +32.50% | -13.56 M Decreased by -104.20% | Decreased by -39.22% Decreased by -54.11% |
| Dec 31, 23 | 36.35 M Increased by +78.83% | -9.15 M Decreased by -967.11% | Decreased by -25.16% Decreased by -584.87% |
| Sep 30, 23 | 34.27 M Increased by +50.13% | -4.39 M Increased by +32.07% | Decreased by -12.81% Increased by +54.75% |
| Jun 30, 23 | 33.47 M Increased by +43.51% | -4.23 M Increased by +32.22% | Decreased by -12.64% Increased by +52.77% |
| Mar 31, 23 | 26.10 M Increased by +18.01% | -6.64 M Decreased by -188.95% | Decreased by -25.45% Decreased by -144.86% |
| Dec 31, 22 | 20.33 M Increased by +0.70% | 1.05 M Increased by +114.22% | Increased by +5.19% Increased by +114.12% |